ICON Public (NASDAQ:ICLR) Given New $262.00 Price Target at Truist Financial

ICON Public (NASDAQ:ICLR) had its target price trimmed by Truist Financial from $284.00 to $262.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other equities analysts also recently commented on ICLR. TD Cowen decreased their target price on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Citigroup reduced their price target on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Robert W. Baird lowered their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 20th. William Blair reissued an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. Finally, Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $283.92.

ICON Public Stock Performance

Shares of ICLR stock opened at $182.64 on Thursday. ICON Public has a 52 week low of $181.51 and a 52 week high of $347.72. The company has a market capitalization of $15.07 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 1.78 and a beta of 1.19. The company has a 50-day simple moving average of $205.46 and a 200 day simple moving average of $250.84. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

Institutional Trading of ICON Public

Large investors have recently made changes to their positions in the company. Motley Fool Wealth Management LLC raised its position in ICON Public by 2.3% during the fourth quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock valued at $13,342,000 after purchasing an additional 1,466 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of ICON Public by 128.2% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 1,166 shares of the medical research company’s stock worth $245,000 after buying an additional 655 shares in the last quarter. Whittier Trust Co. lifted its position in shares of ICON Public by 17.8% during the 4th quarter. Whittier Trust Co. now owns 4,736 shares of the medical research company’s stock worth $993,000 after buying an additional 716 shares during the last quarter. Horizon Investments LLC boosted its stake in ICON Public by 534.0% in the fourth quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock valued at $137,000 after buying an additional 550 shares in the last quarter. Finally, Natixis Advisors LLC grew its position in ICON Public by 6.7% in the fourth quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock valued at $37,279,000 after acquiring an additional 11,177 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.